image credit: Unsplash

After COVID-19 spotlighted supply chain weaknesses, Biden unveils plan to resurrect U.S. drug manufacturing

After investigating America’s supply chains, including those for drugs and pharmaceutical ingredients, the Biden administration has revelations to share—and it’s proposing a sweeping strategy to boost domestic drug production.

Under the plan, the White House is establishing a public-private partnership to select 50 to 100 essential medicines “to be the focus of an enhanced onshoring effort,” the plan says. Further, the government is committing around $60 million to research new technologies to boost domestic API production.

Read More on FiercePharma